Skip to main content
main-content
Erschienen in: Herz 1/2020

25.04.2018 | Review articles

Risk stratification in hypertrophic cardiomyopathy

verfasst von: S. Marrakchi, I. Kammoun, E. Bennour, L. Laroussi, S. Kachboura

Erschienen in: Herz | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Sudden cardiac death (SCD) is the most devastating complication of hypertrophic cardiomyopathy (HCM). The greatest challenge in the management of HCM is identifying those at increased risk, since an implantable cardioverter-defibrillator (ICD) is a potentially life-saving therapy. We sought to summarize the available data on SCD in HCM and provide a clinical perspective on the current differing and somewhat conflicting data on risk stratification, with balanced guidance regarding rational clinical decision-making. Additionally, we sought to determine the status of the current implementation of guidelines compiled by HCM experts worldwide. The HCM Risk-SCD model helps improve the risk stratification of HCM patients for primary prevention of SCD by calculating an individual risk estimate that contributes to the clinical decision-making process. Improved risk stratification is important for decision-making before ICD implantation for the primary prevention of SCD.
Literatur
1.
Zurück zum Zitat Maron BJ, Ommen SR, Semsarian C et al (2014) Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 64(1):83–99 PubMed Maron BJ, Ommen SR, Semsarian C et al (2014) Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 64(1):83–99 PubMed
2.
Zurück zum Zitat Maron BJ, Gardin JM, Flack JM et al (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92(4):785–789 PubMed Maron BJ, Gardin JM, Flack JM et al (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92(4):785–789 PubMed
3.
Zurück zum Zitat Trivedi A, Knight BP (2016) ICD therapy for primary prevention in hypertrophic cardiomyopathy. Arrhythm Electrophysiol Rev 5(3):188–196 PubMedPubMedCentral Trivedi A, Knight BP (2016) ICD therapy for primary prevention in hypertrophic cardiomyopathy. Arrhythm Electrophysiol Rev 5(3):188–196 PubMedPubMedCentral
4.
Zurück zum Zitat Hardarson T, De la Calzada CS, Curiel R, Goodwin JF (1973) Prognosis and mortality of hypertrophic obstructive cardiomyopathy. Lancet 2(7844):1462–1467 PubMed Hardarson T, De la Calzada CS, Curiel R, Goodwin JF (1973) Prognosis and mortality of hypertrophic obstructive cardiomyopathy. Lancet 2(7844):1462–1467 PubMed
5.
Zurück zum Zitat Maron BJ, Olivotto I, Spirito P et al (2000) Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 102(8):858–864 PubMed Maron BJ, Olivotto I, Spirito P et al (2000) Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 102(8):858–864 PubMed
6.
Zurück zum Zitat van der Werf C, van Langen IM, Wilde AAM (2010) Sudden death in the young: what do we know about it and how to prevent? Circ Arrhythm Electrophysiol 3(1):96–104 PubMed van der Werf C, van Langen IM, Wilde AAM (2010) Sudden death in the young: what do we know about it and how to prevent? Circ Arrhythm Electrophysiol 3(1):96–104 PubMed
7.
Zurück zum Zitat Weissler-Snir A, Adler A, Williams L et al (2017) Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge. Eur Heart J 38(22):1728–1737 PubMed Weissler-Snir A, Adler A, Williams L et al (2017) Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge. Eur Heart J 38(22):1728–1737 PubMed
8.
Zurück zum Zitat Rowin EJ, Maron MS (2016) The role of cardiac MRI in the diagnosis and risk stratification of hypertrophic cardiomyopathy. Arrhythm Electrophysiol Rev 5(3):197–202 PubMedPubMedCentral Rowin EJ, Maron MS (2016) The role of cardiac MRI in the diagnosis and risk stratification of hypertrophic cardiomyopathy. Arrhythm Electrophysiol Rev 5(3):197–202 PubMedPubMedCentral
9.
Zurück zum Zitat Maron BJ, Rowin EJ, Casey SA et al (2015) Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol 65(18):1915–1928 PubMed Maron BJ, Rowin EJ, Casey SA et al (2015) Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol 65(18):1915–1928 PubMed
10.
Zurück zum Zitat Maron BJ, Spirito P, Shen WK et al (2007) Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298(4):405–412 PubMed Maron BJ, Spirito P, Shen WK et al (2007) Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298(4):405–412 PubMed
11.
Zurück zum Zitat Gersh BJ, Maron BJ, Bonow RO et al (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 58(25):e212–260 PubMed Gersh BJ, Maron BJ, Bonow RO et al (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 58(25):e212–260 PubMed
12.
Zurück zum Zitat Kawashiri M, Hayashi K, Konno T et al (2014) Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects. Heart Vessels 29(2):129–141 PubMed Kawashiri M, Hayashi K, Konno T et al (2014) Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects. Heart Vessels 29(2):129–141 PubMed
13.
Zurück zum Zitat Konno T, Shimizu M, Ino H et al (2003) A novel missense mutation in the myosin binding protein-C gene is responsible for hypertrophic cardiomyopathy with left ventricular dysfunction and dilation in elderly patients. J Am Coll Cardiol 41(5):781–786 PubMed Konno T, Shimizu M, Ino H et al (2003) A novel missense mutation in the myosin binding protein-C gene is responsible for hypertrophic cardiomyopathy with left ventricular dysfunction and dilation in elderly patients. J Am Coll Cardiol 41(5):781–786 PubMed
14.
Zurück zum Zitat Konno T, Chang S, Seidman JG, Seidman CE (2010) Genetics of hypertrophic cardiomyopathy. Curr Opin Cardiol 25(3):205–209 PubMed Konno T, Chang S, Seidman JG, Seidman CE (2010) Genetics of hypertrophic cardiomyopathy. Curr Opin Cardiol 25(3):205–209 PubMed
15.
Zurück zum Zitat Disertori M, Masè M, Ravelli F (2017) Myocardial fibrosis predicts ventricular tachyarrhythmias. Trends Cardiovasc Med 27(5):363–372 PubMed Disertori M, Masè M, Ravelli F (2017) Myocardial fibrosis predicts ventricular tachyarrhythmias. Trends Cardiovasc Med 27(5):363–372 PubMed
16.
Zurück zum Zitat Varnava AM, Elliott PM, Mahon N et al (2001) Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol 88(3):275–279 PubMed Varnava AM, Elliott PM, Mahon N et al (2001) Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol 88(3):275–279 PubMed
17.
Zurück zum Zitat Basso C, Thiene G, Corrado D et al (2000) Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 31(8):988–998 PubMed Basso C, Thiene G, Corrado D et al (2000) Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 31(8):988–998 PubMed
18.
Zurück zum Zitat Chan RH, Maron BJ, Olivotto I et al (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130(6):484–495 PubMed Chan RH, Maron BJ, Olivotto I et al (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130(6):484–495 PubMed
19.
Zurück zum Zitat Nguyen TP, Qu Z, Weiss JN (2014) Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils. J Mol Cell Cardiol 70:83–91 PubMed Nguyen TP, Qu Z, Weiss JN (2014) Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils. J Mol Cell Cardiol 70:83–91 PubMed
20.
Zurück zum Zitat Morita N, Mandel WJ, Kobayashi Y, Karagueuzian HS (2014) Cardiac fibrosis as a determinant of ventricular tachyarrhythmias. J Arrhythm 30(6):389–394 PubMedPubMedCentral Morita N, Mandel WJ, Kobayashi Y, Karagueuzian HS (2014) Cardiac fibrosis as a determinant of ventricular tachyarrhythmias. J Arrhythm 30(6):389–394 PubMedPubMedCentral
21.
Zurück zum Zitat de Jong S, van Veen TAB, van Rijen HVM, de Bakker JMT (2011) Fibrosis and cardiac arrhythmias. J Cardiovasc Pharmacol 57(6):630–638 PubMed de Jong S, van Veen TAB, van Rijen HVM, de Bakker JMT (2011) Fibrosis and cardiac arrhythmias. J Cardiovasc Pharmacol 57(6):630–638 PubMed
22.
Zurück zum Zitat Elliott PM, Anastasakis A, Borger MA et al (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35(39):2733–2779 Elliott PM, Anastasakis A, Borger MA et al (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35(39):2733–2779
23.
Zurück zum Zitat Maron BJ, McKenna WJ, Danielson GK et al (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42(9):1687–1713 PubMed Maron BJ, McKenna WJ, Danielson GK et al (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42(9):1687–1713 PubMed
24.
Zurück zum Zitat Betensky BP, Dixit S (2014) Sudden cardiac death in patients with nonischemic cardiomyopathy. Indian Heart J 66:S35–45 PubMedPubMedCentral Betensky BP, Dixit S (2014) Sudden cardiac death in patients with nonischemic cardiomyopathy. Indian Heart J 66:S35–45 PubMedPubMedCentral
25.
Zurück zum Zitat Veselka J, Anavekar NS, Charron P (2017) Hypertrophic obstructive cardiomyopathy. Lancet 389(10075):1253–1267 PubMed Veselka J, Anavekar NS, Charron P (2017) Hypertrophic obstructive cardiomyopathy. Lancet 389(10075):1253–1267 PubMed
26.
Zurück zum Zitat Maron BJ, Haas TS, Shannon KM et al (2009) Long-term survival after cardiac arrest in hypertrophic cardiomyopathy. Heart Rhythm 6(7):993–997 PubMed Maron BJ, Haas TS, Shannon KM et al (2009) Long-term survival after cardiac arrest in hypertrophic cardiomyopathy. Heart Rhythm 6(7):993–997 PubMed
27.
Zurück zum Zitat Elliott PM, Sharma S, Varnava A et al (1999) Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 33(6):1596–1601 PubMed Elliott PM, Sharma S, Varnava A et al (1999) Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 33(6):1596–1601 PubMed
28.
Zurück zum Zitat Elliott PM, Poloniecki J, Dickie S et al (2000) Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 36(7):2212–2218 PubMed Elliott PM, Poloniecki J, Dickie S et al (2000) Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 36(7):2212–2218 PubMed
29.
Zurück zum Zitat Olivotto I, Maron MS, Adabag AS et al (2005) Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 46(3):480–487 PubMed Olivotto I, Maron MS, Adabag AS et al (2005) Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 46(3):480–487 PubMed
30.
Zurück zum Zitat Maron BJ, Roberts WC, Epstein SE (1982) Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 65(7):1388–1394 PubMed Maron BJ, Roberts WC, Epstein SE (1982) Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 65(7):1388–1394 PubMed
31.
Zurück zum Zitat Maron BJ, Rowin EJ, Casey SA et al (2013) Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation 127(5):585–593 PubMed Maron BJ, Rowin EJ, Casey SA et al (2013) Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation 127(5):585–593 PubMed
32.
Zurück zum Zitat Monserrat L, Elliott PM, Gimeno JR et al (2003) Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 42(5):873–879 PubMed Monserrat L, Elliott PM, Gimeno JR et al (2003) Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 42(5):873–879 PubMed
33.
Zurück zum Zitat Gimeno JR, Tomé-Esteban M, Lofiego C et al (2009) Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J 30(21):2599–2605 PubMed Gimeno JR, Tomé-Esteban M, Lofiego C et al (2009) Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J 30(21):2599–2605 PubMed
34.
Zurück zum Zitat Dimitrow PP, Chojnowska L, Rudzinski T et al (2010) Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up. Eur Heart J 31(24):3084–3093 PubMed Dimitrow PP, Chojnowska L, Rudzinski T et al (2010) Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up. Eur Heart J 31(24):3084–3093 PubMed
35.
Zurück zum Zitat Adabag AS, Casey SA, Kuskowski MA et al (2005) Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 45(5):697–704 PubMed Adabag AS, Casey SA, Kuskowski MA et al (2005) Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 45(5):697–704 PubMed
36.
Zurück zum Zitat Spirito P, Rapezzi C, Autore C et al (1994) Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 90(6):2743–2747 PubMed Spirito P, Rapezzi C, Autore C et al (1994) Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 90(6):2743–2747 PubMed
37.
Zurück zum Zitat Borggrefe M, Kuhn H, Königer HH et al (1983) Arrhythmias in hypertrophic obstructive and non-obstructive cardiomyopathy. Eur Heart J 4(Suppl F):245–251 PubMed Borggrefe M, Kuhn H, Königer HH et al (1983) Arrhythmias in hypertrophic obstructive and non-obstructive cardiomyopathy. Eur Heart J 4(Suppl F):245–251 PubMed
38.
Zurück zum Zitat Viswanathan K, Suszko AM, Das M et al (2016) Rapid device-detected nonsustained ventricular tachycardia in the risk stratification of hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 39(7):642–651 PubMed Viswanathan K, Suszko AM, Das M et al (2016) Rapid device-detected nonsustained ventricular tachycardia in the risk stratification of hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 39(7):642–651 PubMed
39.
Zurück zum Zitat Francia P, Santini D, Musumeci B et al (2014) Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 25(11):1180–1187 PubMed Francia P, Santini D, Musumeci B et al (2014) Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 25(11):1180–1187 PubMed
40.
Zurück zum Zitat Behr ER, Elliott P, McKenna WJ (2002) Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. Card Electrophysiol Rev 6(4):482–486 PubMed Behr ER, Elliott P, McKenna WJ (2002) Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. Card Electrophysiol Rev 6(4):482–486 PubMed
41.
Zurück zum Zitat Spirito P, Maron BJ (1990) Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. J Am Coll Cardiol 15(7):1521–1526 PubMed Spirito P, Maron BJ (1990) Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. J Am Coll Cardiol 15(7):1521–1526 PubMed
42.
Zurück zum Zitat Spirito P, Bellone P, Harris KM et al (2000) Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342(24):1778–1785 PubMed Spirito P, Bellone P, Harris KM et al (2000) Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342(24):1778–1785 PubMed
43.
Zurück zum Zitat Sorajja P, Nishimura RA, Ommen SR et al (2006) Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. J Am Soc Echocardiogr 19(6):788–795 PubMed Sorajja P, Nishimura RA, Ommen SR et al (2006) Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. J Am Soc Echocardiogr 19(6):788–795 PubMed
44.
Zurück zum Zitat Elliott P, Gimeno J, Tomé M, McKenna W (2006) Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. Eur Heart J 27(24):3073 (author reply 3073–3074) PubMed Elliott P, Gimeno J, Tomé M, McKenna W (2006) Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. Eur Heart J 27(24):3073 (author reply 3073–3074) PubMed
45.
Zurück zum Zitat Christiaans I, van Engelen K, van Langen IM et al (2010) Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace 12(3):313–321 PubMed Christiaans I, van Engelen K, van Langen IM et al (2010) Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace 12(3):313–321 PubMed
46.
Zurück zum Zitat Maki S, Ikeda H, Muro A et al (1998) Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 82(6):774–778 PubMed Maki S, Ikeda H, Muro A et al (1998) Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 82(6):774–778 PubMed
47.
Zurück zum Zitat Bos JM, Maron BJ, Ackerman MJ et al (2010) Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. Am J Cardiol 106(10):1481–1486 PubMed Bos JM, Maron BJ, Ackerman MJ et al (2010) Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. Am J Cardiol 106(10):1481–1486 PubMed
48.
Zurück zum Zitat Spirito P, Autore C, Rapezzi C et al (2009) Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 119(13):1703–1710 PubMed Spirito P, Autore C, Rapezzi C et al (2009) Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 119(13):1703–1710 PubMed
49.
Zurück zum Zitat O’Mahony C, Jichi F, Pavlou M et al (2014) A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 35(30):2010–2020 PubMed O’Mahony C, Jichi F, Pavlou M et al (2014) A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 35(30):2010–2020 PubMed
50.
Zurück zum Zitat Li PR, Li XL, Xu F et al (2016) Clinical characteristics and outcome of patients with dilated-hypertrophic cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi 44(4):327–330 PubMed Li PR, Li XL, Xu F et al (2016) Clinical characteristics and outcome of patients with dilated-hypertrophic cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi 44(4):327–330 PubMed
51.
Zurück zum Zitat Minami Y, Haruki S, Yashiro B et al (2016) Enlarged left atrium and sudden death risk in hypertrophic cardiomyopathy patients with or without atrial fibrillation. J Cardiol 68(6):478–484 PubMed Minami Y, Haruki S, Yashiro B et al (2016) Enlarged left atrium and sudden death risk in hypertrophic cardiomyopathy patients with or without atrial fibrillation. J Cardiol 68(6):478–484 PubMed
53.
Zurück zum Zitat Maron MS, Olivotto I, Betocchi S et al (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348(4):295–303 PubMed Maron MS, Olivotto I, Betocchi S et al (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348(4):295–303 PubMed
54.
Zurück zum Zitat McLeod CJ, Ommen SR, Ackerman MJ et al (2007) Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J 28(21):2583–2588 PubMed McLeod CJ, Ommen SR, Ackerman MJ et al (2007) Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J 28(21):2583–2588 PubMed
55.
Zurück zum Zitat Vriesendorp PA, Liebregts M, Steggerda RC et al (2014) Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. JACC Heart Fail 2(6):630–636 PubMed Vriesendorp PA, Liebregts M, Steggerda RC et al (2014) Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. JACC Heart Fail 2(6):630–636 PubMed
56.
Zurück zum Zitat Ball W, Ivanov J, Rakowski H et al (2011) Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol 58(22):2313–2321 PubMed Ball W, Ivanov J, Rakowski H et al (2011) Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol 58(22):2313–2321 PubMed
57.
Zurück zum Zitat Pozios I, Corona-Villalobos C, Sorensen LL et al (2015) Comparison of outcomes in patients with nonobstructive, labile-obstructive, and chronically obstructive hypertrophic cardiomyopathy. Am J Cardiol 116(6):938–944 PubMedPubMedCentral Pozios I, Corona-Villalobos C, Sorensen LL et al (2015) Comparison of outcomes in patients with nonobstructive, labile-obstructive, and chronically obstructive hypertrophic cardiomyopathy. Am J Cardiol 116(6):938–944 PubMedPubMedCentral
58.
Zurück zum Zitat Frenneaux MP, Counihan PJ, Caforio AL et al (1990) Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 82(6):1995–2002 PubMed Frenneaux MP, Counihan PJ, Caforio AL et al (1990) Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 82(6):1995–2002 PubMed
59.
Zurück zum Zitat Olivotto I, Maron BJ, Montereggi A et al (1999) Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 33(7):2044–2051 PubMed Olivotto I, Maron BJ, Montereggi A et al (1999) Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 33(7):2044–2051 PubMed
60.
Zurück zum Zitat Ciampi Q, Betocchi S, Lombardi R et al (2002) Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. J Am Coll Cardiol 40(2):278–284 PubMed Ciampi Q, Betocchi S, Lombardi R et al (2002) Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. J Am Coll Cardiol 40(2):278–284 PubMed
61.
Zurück zum Zitat Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ (1991) Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation 84(2):686–696 PubMed Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ (1991) Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation 84(2):686–696 PubMed
62.
Zurück zum Zitat Campbell R, Manyari DE, McKenna WJ, Frenneaux M (2003) What is the mechanism of abnormal blood pressure response on exercise in hypertrophic cardiomyopathy? J Am Coll Cardiol 41(11):2102 PubMed Campbell R, Manyari DE, McKenna WJ, Frenneaux M (2003) What is the mechanism of abnormal blood pressure response on exercise in hypertrophic cardiomyopathy? J Am Coll Cardiol 41(11):2102 PubMed
63.
Zurück zum Zitat Sadoul N, Prasad K, Elliott PM et al (1997) Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 96(9):2987–2991 PubMed Sadoul N, Prasad K, Elliott PM et al (1997) Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 96(9):2987–2991 PubMed
64.
Zurück zum Zitat Desai MY, Bhonsale A, Patel P et al (2014) Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes. JACC Cardiovasc Imaging 7(1):26–36 PubMed Desai MY, Bhonsale A, Patel P et al (2014) Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes. JACC Cardiovasc Imaging 7(1):26–36 PubMed
65.
Zurück zum Zitat Moravsky G, Ofek E, Rakowski H et al (2013) Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging 6(5):587–596 PubMed Moravsky G, Ofek E, Rakowski H et al (2013) Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging 6(5):587–596 PubMed
66.
Zurück zum Zitat Briasoulis A, Mallikethi-Reddy S, Palla M et al (2015) Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. Heart 101(17):1406–1411 PubMed Briasoulis A, Mallikethi-Reddy S, Palla M et al (2015) Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. Heart 101(17):1406–1411 PubMed
67.
Zurück zum Zitat Maron MS, Appelbaum E, Harrigan CJ et al (2008) Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 1(3):184–191 PubMed Maron MS, Appelbaum E, Harrigan CJ et al (2008) Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 1(3):184–191 PubMed
68.
Zurück zum Zitat Moon JCC, Reed E, Sheppard MN et al (2004) The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43(12):2260–2264 PubMed Moon JCC, Reed E, Sheppard MN et al (2004) The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43(12):2260–2264 PubMed
69.
Zurück zum Zitat van der Bijl P, Delgado V, Bax JJ (2016) Noninvasive imaging markers associated with sudden cardiac death. Trends Cardiovasc Med 26(4):348–360 PubMed van der Bijl P, Delgado V, Bax JJ (2016) Noninvasive imaging markers associated with sudden cardiac death. Trends Cardiovasc Med 26(4):348–360 PubMed
70.
Zurück zum Zitat Green JJ, Berger JS, Kramer CM, Salerno M (2012) Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 5(4):370–377 PubMed Green JJ, Berger JS, Kramer CM, Salerno M (2012) Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 5(4):370–377 PubMed
71.
Zurück zum Zitat Adabag AS, Maron BJ, Appelbaum E et al (2008) Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 51(14):1369–1374 PubMed Adabag AS, Maron BJ, Appelbaum E et al (2008) Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 51(14):1369–1374 PubMed
72.
Zurück zum Zitat Kwon DH, Setser RM, Popović ZB et al (2008) Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. Int J Cardiovasc Imaging 24(6):617–625 PubMed Kwon DH, Setser RM, Popović ZB et al (2008) Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. Int J Cardiovasc Imaging 24(6):617–625 PubMed
73.
Zurück zum Zitat Rubinshtein R, Glockner JF, Ommen SR et al (2010) Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 3(1):51–58 PubMed Rubinshtein R, Glockner JF, Ommen SR et al (2010) Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 3(1):51–58 PubMed
74.
Zurück zum Zitat Inada K, Seiler J, Roberts-Thomson KC et al (2011) Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 22(1):41–48 PubMed Inada K, Seiler J, Roberts-Thomson KC et al (2011) Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 22(1):41–48 PubMed
75.
Zurück zum Zitat Weng Z, Yao J, Chan RH et al (2016) Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging 9(12):1392–1402 PubMed Weng Z, Yao J, Chan RH et al (2016) Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging 9(12):1392–1402 PubMed
77.
Zurück zum Zitat Ismail TF, Jabbour A, Gulati A et al (2014) Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart 100(23):1851–1858 PubMed Ismail TF, Jabbour A, Gulati A et al (2014) Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart 100(23):1851–1858 PubMed
78.
Zurück zum Zitat Chan RH, Maron BJ, Olivotto I et al (2015) Significance of late gadolinium enhancement at right ventricular attachment to ventricular septum in patients with hypertrophic cardiomyopathy. Am J Cardiol 116(3):436–441 PubMed Chan RH, Maron BJ, Olivotto I et al (2015) Significance of late gadolinium enhancement at right ventricular attachment to ventricular septum in patients with hypertrophic cardiomyopathy. Am J Cardiol 116(3):436–441 PubMed
79.
Zurück zum Zitat Sakamoto N, Kawamura Y, Sato N et al (2015) Late gadolinium enhancement on cardiac magnetic resonance represents the depolarizing and repolarizing electrically damaged foci causing malignant ventricular arrhythmia in hypertrophic cardiomyopathy. Heart Rhythm 12(6):1276–1284 PubMed Sakamoto N, Kawamura Y, Sato N et al (2015) Late gadolinium enhancement on cardiac magnetic resonance represents the depolarizing and repolarizing electrically damaged foci causing malignant ventricular arrhythmia in hypertrophic cardiomyopathy. Heart Rhythm 12(6):1276–1284 PubMed
81.
Zurück zum Zitat Doesch C, Tülümen E, Akin I et al (2017) Incremental benefit of late gadolinium cardiac magnetic resonance imaging for risk stratification in patients with hypertrophic cardiomyopathy. Sci Rep 7(1):6336 PubMedPubMedCentral Doesch C, Tülümen E, Akin I et al (2017) Incremental benefit of late gadolinium cardiac magnetic resonance imaging for risk stratification in patients with hypertrophic cardiomyopathy. Sci Rep 7(1):6336 PubMedPubMedCentral
82.
Zurück zum Zitat Stroumpoulis KI, Pantazopoulos IN, Xanthos TT (2010) Hypertrophic cardiomyopathy and sudden cardiac death. World J Cardiol 2(9):289–298 PubMedPubMedCentral Stroumpoulis KI, Pantazopoulos IN, Xanthos TT (2010) Hypertrophic cardiomyopathy and sudden cardiac death. World J Cardiol 2(9):289–298 PubMedPubMedCentral
83.
Zurück zum Zitat Olivotto I, Maron BJ, Appelbaum E et al (2010) Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 106(2):261–267 PubMed Olivotto I, Maron BJ, Appelbaum E et al (2010) Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 106(2):261–267 PubMed
84.
Zurück zum Zitat Chan RH, Maron BJ, Olivotto I et al (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130(6):484–495 PubMed Chan RH, Maron BJ, Olivotto I et al (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130(6):484–495 PubMed
85.
Zurück zum Zitat Bruder O, Wagner A, Jensen CJ et al (2010) Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 56(11):875–887 PubMed Bruder O, Wagner A, Jensen CJ et al (2010) Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 56(11):875–887 PubMed
86.
Zurück zum Zitat O’Hanlon R, Grasso A, Roughton M et al (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56(11):867–874 PubMed O’Hanlon R, Grasso A, Roughton M et al (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56(11):867–874 PubMed
87.
Zurück zum Zitat Choudhury L, Mahrholdt H, Wagner A et al (2002) Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40(12):2156–2164 PubMed Choudhury L, Mahrholdt H, Wagner A et al (2002) Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40(12):2156–2164 PubMed
88.
Zurück zum Zitat Berliner JI, Kino A, Carr JC et al (2013) Cardiac computed tomographic imaging to evaluate myocardial scarring/fibrosis in patients with hypertrophic cardiomyopathy: a comparison with cardiac magnetic resonance imaging. Int J Cardiovasc Imaging 29(1):191–197 PubMed Berliner JI, Kino A, Carr JC et al (2013) Cardiac computed tomographic imaging to evaluate myocardial scarring/fibrosis in patients with hypertrophic cardiomyopathy: a comparison with cardiac magnetic resonance imaging. Int J Cardiovasc Imaging 29(1):191–197 PubMed
89.
Zurück zum Zitat Choudhury L, Rigolin VH, Bonow RO (2017) Integrated imaging in hypertrophic cardiomyopathy. Am J Cardiol 119(2):328–339 PubMed Choudhury L, Rigolin VH, Bonow RO (2017) Integrated imaging in hypertrophic cardiomyopathy. Am J Cardiol 119(2):328–339 PubMed
90.
Zurück zum Zitat Maron MS, Finley JJ, Bos JM et al (2008) Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 118(15):1541–1549 PubMed Maron MS, Finley JJ, Bos JM et al (2008) Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 118(15):1541–1549 PubMed
91.
Zurück zum Zitat Hanneman K, Crean AM, Williams L et al (2014) Cardiac magnetic resonance imaging findings predict major adverse events in apical hypertrophic cardiomyopathy. J Thorac Imaging 29(6):331–339 PubMed Hanneman K, Crean AM, Williams L et al (2014) Cardiac magnetic resonance imaging findings predict major adverse events in apical hypertrophic cardiomyopathy. J Thorac Imaging 29(6):331–339 PubMed
92.
Zurück zum Zitat Sakamoto T, Tei C, Murayama M et al (1976) Giant T wave inversion as a manifestation of asymmetrical apical hypertrophy (AAH) of the left ventricle. Echocardiographic and ultrasono-cardiotomographic study. Jpn Heart J 17(5):611–629 PubMed Sakamoto T, Tei C, Murayama M et al (1976) Giant T wave inversion as a manifestation of asymmetrical apical hypertrophy (AAH) of the left ventricle. Echocardiographic and ultrasono-cardiotomographic study. Jpn Heart J 17(5):611–629 PubMed
93.
Zurück zum Zitat Trojan MKB, Biederman RW (2017) Management of an asymptomatic patient with the apical variant of hypertrophic cardiomyopathy. Echocardiography 34(7):1092–1095 PubMed Trojan MKB, Biederman RW (2017) Management of an asymptomatic patient with the apical variant of hypertrophic cardiomyopathy. Echocardiography 34(7):1092–1095 PubMed
94.
Zurück zum Zitat Harris KM, Spirito P, Maron MS et al (2006) Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 114(3):216–225 PubMed Harris KM, Spirito P, Maron MS et al (2006) Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 114(3):216–225 PubMed
95.
Zurück zum Zitat Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA 287(10):1308–1320 PubMed Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA 287(10):1308–1320 PubMed
96.
Zurück zum Zitat Frey N, Luedde M, Katus HA (2011) Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol 9(2):91–100 PubMed Frey N, Luedde M, Katus HA (2011) Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol 9(2):91–100 PubMed
98.
Zurück zum Zitat Maron BJ, Maron MS, Semsarian C (2012) Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. Heart Rhythm 9(1):57–63 PubMed Maron BJ, Maron MS, Semsarian C (2012) Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. Heart Rhythm 9(1):57–63 PubMed
99.
Zurück zum Zitat Wang J, Wang Y, Zou Y et al (2014) Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy. Eur J Heart Fail 16(9):950–957 PubMed Wang J, Wang Y, Zou Y et al (2014) Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy. Eur J Heart Fail 16(9):950–957 PubMed
100.
Zurück zum Zitat Chida A, Inai K, Sato H et al (2017) Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy. Heart Vessels 32(6):700–707 PubMed Chida A, Inai K, Sato H et al (2017) Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy. Heart Vessels 32(6):700–707 PubMed
101.
Zurück zum Zitat Ingles J, Doolan A, Chiu C (2005) Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet 42(10):e59 PubMedPubMedCentral Ingles J, Doolan A, Chiu C (2005) Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet 42(10):e59 PubMedPubMedCentral
102.
Zurück zum Zitat Guo X, Fan C, Wang Y et al (2017) Genetic anticipation in a special form of hypertrophic cardiomyopathy with sudden cardiac death in a family with 74 members across 5 generations. Medicine (Baltimore) 96(11):e6249 Guo X, Fan C, Wang Y et al (2017) Genetic anticipation in a special form of hypertrophic cardiomyopathy with sudden cardiac death in a family with 74 members across 5 generations. Medicine (Baltimore) 96(11):e6249
103.
Zurück zum Zitat Fraiche A, Hypertrophic Cardiomyopathy WA (2016) New evidence since the 2011 American Cardiology of Cardiology Foundation and American Heart Association guideline. Curr Cardiol Rep 18(8):70 PubMed Fraiche A, Hypertrophic Cardiomyopathy WA (2016) New evidence since the 2011 American Cardiology of Cardiology Foundation and American Heart Association guideline. Curr Cardiol Rep 18(8):70 PubMed
104.
Zurück zum Zitat Maron BJ, Mathenge R, Casey SA et al (1999) Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol 33(6):1590–1595 PubMed Maron BJ, Mathenge R, Casey SA et al (1999) Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol 33(6):1590–1595 PubMed
105.
Zurück zum Zitat Zou Y, Song L, Wang Z et al (2004) Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med 116(1):14–18 PubMed Zou Y, Song L, Wang Z et al (2004) Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med 116(1):14–18 PubMed
106.
Zurück zum Zitat Maron BJ, Spirito P, Roman MJ et al (2004) Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study). Am J Cardiol 93(12):1510–1514 PubMed Maron BJ, Spirito P, Roman MJ et al (2004) Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study). Am J Cardiol 93(12):1510–1514 PubMed
107.
Zurück zum Zitat Maro EE, Janabi M, Kaushik R (2006) Clinical and echocardiographic study of hypertrophic cardiomyopathy in Tanzania. Trop Doct 36(4):225–227 PubMed Maro EE, Janabi M, Kaushik R (2006) Clinical and echocardiographic study of hypertrophic cardiomyopathy in Tanzania. Trop Doct 36(4):225–227 PubMed
108.
Zurück zum Zitat Ng CT, Chee TS, Ling LF et al (2011) Prevalence of hypertrophic cardiomyopathy on an electrocardiogram-based pre-participation screening programme in a young male South-East Asian population: results from the Singapore Armed Forces Electrocardiogram and Echocardiogram screening protocol. Europace 13(6):883–888 PubMed Ng CT, Chee TS, Ling LF et al (2011) Prevalence of hypertrophic cardiomyopathy on an electrocardiogram-based pre-participation screening programme in a young male South-East Asian population: results from the Singapore Armed Forces Electrocardiogram and Echocardiogram screening protocol. Europace 13(6):883–888 PubMed
109.
Zurück zum Zitat Lipshultz SE, Sleeper LA, Towbin JA et al (2003) The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 348(17):1647–1655 PubMed Lipshultz SE, Sleeper LA, Towbin JA et al (2003) The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 348(17):1647–1655 PubMed
110.
Zurück zum Zitat Nugent AW, Daubeney PEF, Chondros P et al (2005) Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation 112(9):1332–1338 PubMed Nugent AW, Daubeney PEF, Chondros P et al (2005) Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation 112(9):1332–1338 PubMed
111.
Zurück zum Zitat Olivotto I, Girolami F, Sciagrà R et al (2011) Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol 58(8):839–848 PubMed Olivotto I, Girolami F, Sciagrà R et al (2011) Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol 58(8):839–848 PubMed
112.
Zurück zum Zitat Watkins H, McKenna WJ, Thierfelder L et al (1995) Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 332(16):1058–1064 PubMed Watkins H, McKenna WJ, Thierfelder L et al (1995) Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 332(16):1058–1064 PubMed
113.
Zurück zum Zitat Van Driest SL, Maron BJ, Ackerman MJ (2004) From malignant mutations to malignant domains: the continuing search for prognostic significance in the mutant genes causing hypertrophic cardiomyopathy. Heart 90(1):7–8 PubMedPubMedCentral Van Driest SL, Maron BJ, Ackerman MJ (2004) From malignant mutations to malignant domains: the continuing search for prognostic significance in the mutant genes causing hypertrophic cardiomyopathy. Heart 90(1):7–8 PubMedPubMedCentral
114.
Zurück zum Zitat O’Mahony C, Tome-Esteban M, Lambiase PD et al (2013) A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart 99(8):534–541 PubMed O’Mahony C, Tome-Esteban M, Lambiase PD et al (2013) A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart 99(8):534–541 PubMed
115.
Zurück zum Zitat Efthimiadis GK, Parcharidou DG, Giannakoulas G et al (2009) Left ventricular outflow tract obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 104(5):695–699 PubMed Efthimiadis GK, Parcharidou DG, Giannakoulas G et al (2009) Left ventricular outflow tract obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 104(5):695–699 PubMed
116.
Zurück zum Zitat Olivotto I, Cecchi F, Poggesi C, Yacoub MH (2012) Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail 5(4):535–546 PubMed Olivotto I, Cecchi F, Poggesi C, Yacoub MH (2012) Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail 5(4):535–546 PubMed
117.
Zurück zum Zitat Maron BJ, Casey SA, Chan RH et al (2015) Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy. Am J Cardiol 116(5):757–764 PubMed Maron BJ, Casey SA, Chan RH et al (2015) Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy. Am J Cardiol 116(5):757–764 PubMed
118.
Zurück zum Zitat Zhu SH, Li Y, Huang W et al (2017) Feasibility of the 2014 European guidelines risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy in Chinese patients. Zhonghua Xin Xue Guan Bing Za Zhi 45(5):404–408 PubMed Zhu SH, Li Y, Huang W et al (2017) Feasibility of the 2014 European guidelines risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy in Chinese patients. Zhonghua Xin Xue Guan Bing Za Zhi 45(5):404–408 PubMed
119.
Zurück zum Zitat Fernández A, Quiroga A, Ochoa JP et al (2016) Validation of the 2014 European Society of Cardiology sudden cardiac death risk prediction model in hypertrophic cardiomyopathy in a Reference Center in South America. Am J Cardiol 118(1):121–126 PubMed Fernández A, Quiroga A, Ochoa JP et al (2016) Validation of the 2014 European Society of Cardiology sudden cardiac death risk prediction model in hypertrophic cardiomyopathy in a Reference Center in South America. Am J Cardiol 118(1):121–126 PubMed
120.
Zurück zum Zitat Vriesendorp PA, Schinkel AFL, Liebregts M et al (2015) Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol 8(4):829–835 PubMed Vriesendorp PA, Schinkel AFL, Liebregts M et al (2015) Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol 8(4):829–835 PubMed
121.
Zurück zum Zitat Elliott PM, Gimeno Blanes JR, Mahon NG et al (2001) Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 357(9254):420–424 PubMed Elliott PM, Gimeno Blanes JR, Mahon NG et al (2001) Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 357(9254):420–424 PubMed
122.
Zurück zum Zitat Vriesendorp PA, Schinkel AFL, Van Cleemput J et al (2013) Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications. Am Heart J 166(3):496–502 PubMed Vriesendorp PA, Schinkel AFL, Van Cleemput J et al (2013) Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications. Am Heart J 166(3):496–502 PubMed
123.
Zurück zum Zitat Girolami F, Ho CY, Semsarian C et al (2010) Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol 55(14):1444–1453 PubMed Girolami F, Ho CY, Semsarian C et al (2010) Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol 55(14):1444–1453 PubMed
124.
Zurück zum Zitat Ommen SR, Maron BJ, Olivotto I et al (2005) Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 46(3):470–476 PubMed Ommen SR, Maron BJ, Olivotto I et al (2005) Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 46(3):470–476 PubMed
125.
Zurück zum Zitat ten Cate FJ, Soliman OII, Michels M et al (2010) Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail 3(3):362–369 PubMed ten Cate FJ, Soliman OII, Michels M et al (2010) Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail 3(3):362–369 PubMed
126.
Zurück zum Zitat Veselka J, Tomašov P, Zemánek D (2011) Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy: a randomized study with a follow-up up to 11 years. Can J Cardiol 27(6):763–767 PubMed Veselka J, Tomašov P, Zemánek D (2011) Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy: a randomized study with a follow-up up to 11 years. Can J Cardiol 27(6):763–767 PubMed
127.
Zurück zum Zitat Jensen MK, Prinz C, Horstkotte D et al (2013) Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart 99(14):1012–1017 PubMed Jensen MK, Prinz C, Horstkotte D et al (2013) Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart 99(14):1012–1017 PubMed
128.
Zurück zum Zitat Sugrue A, Killu AM, DeSimone CV et al (2017) Utility of T‑wave amplitude as a non-invasive risk marker of sudden cardiac death in hypertrophic cardiomyopathy. Open Heart 4(1):e561 PubMedPubMedCentral Sugrue A, Killu AM, DeSimone CV et al (2017) Utility of T‑wave amplitude as a non-invasive risk marker of sudden cardiac death in hypertrophic cardiomyopathy. Open Heart 4(1):e561 PubMedPubMedCentral
129.
Zurück zum Zitat Akboğa MK, Gülcihan Balcı K, Yılmaz S et al (2017) Tp-e interval and Tp-e/QTc ratio as novel surrogate markers for prediction of ventricular arrhythmic events in hypertrophic cardiomyopathy. Anatol J Cardiol 18(1):48–53 PubMedPubMedCentral Akboğa MK, Gülcihan Balcı K, Yılmaz S et al (2017) Tp-e interval and Tp-e/QTc ratio as novel surrogate markers for prediction of ventricular arrhythmic events in hypertrophic cardiomyopathy. Anatol J Cardiol 18(1):48–53 PubMedPubMedCentral
130.
Zurück zum Zitat Castro-Torres Y (2017) Tp-e interval and Tp-e/QTc ratio: new choices for risk stratification of arrhythmic events in patients with hypertrophic cardiomyopathy. Anatol J Cardiol 17(6):493 PubMedPubMedCentral Castro-Torres Y (2017) Tp-e interval and Tp-e/QTc ratio: new choices for risk stratification of arrhythmic events in patients with hypertrophic cardiomyopathy. Anatol J Cardiol 17(6):493 PubMedPubMedCentral
131.
Zurück zum Zitat Castro-Torres Y, Carmona-Puerta R, Katholi RE (2015) Ventricular repolarization markers for predicting malignant arrhythmias in clinical practice. World J Clin Cases 3(8):705–720 PubMedPubMedCentral Castro-Torres Y, Carmona-Puerta R, Katholi RE (2015) Ventricular repolarization markers for predicting malignant arrhythmias in clinical practice. World J Clin Cases 3(8):705–720 PubMedPubMedCentral
132.
Zurück zum Zitat Gupta P, Patel C, Patel H et al (2008) T(p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol 41(6):567–574 PubMed Gupta P, Patel C, Patel H et al (2008) T(p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol 41(6):567–574 PubMed
133.
Zurück zum Zitat Saumarez RC, Pytkowski M, Sterlinski M et al (2008) Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J 29(13):1653–1661 PubMed Saumarez RC, Pytkowski M, Sterlinski M et al (2008) Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J 29(13):1653–1661 PubMed
134.
Zurück zum Zitat Magrì D, Santolamazza C (2017) Cardiopulmonary exercise test in hypertrophic cardiomyopathy. Ann Am Thorac Soc 14(Supplement_1):S102–S109 PubMed Magrì D, Santolamazza C (2017) Cardiopulmonary exercise test in hypertrophic cardiomyopathy. Ann Am Thorac Soc 14(Supplement_1):S102–S109 PubMed
135.
Zurück zum Zitat Finocchiaro G, Haddad F, Knowles JW et al (2015) Cardiopulmonary responses and prognosis in hypertrophic cardiomyopathy: a potential role for comprehensive noninvasive hemodynamic assessment. JACC Heart Fail 3(5):408–418 PubMed Finocchiaro G, Haddad F, Knowles JW et al (2015) Cardiopulmonary responses and prognosis in hypertrophic cardiomyopathy: a potential role for comprehensive noninvasive hemodynamic assessment. JACC Heart Fail 3(5):408–418 PubMed
136.
Zurück zum Zitat Belardinelli R, Lacalaprice F, Carle F et al (2003) Exercise-induced myocardial ischaemia detected by cardiopulmonary exercise testing. Eur Heart J 24(14):1304–1313 PubMed Belardinelli R, Lacalaprice F, Carle F et al (2003) Exercise-induced myocardial ischaemia detected by cardiopulmonary exercise testing. Eur Heart J 24(14):1304–1313 PubMed
137.
Zurück zum Zitat Masri A, Pierson LM, Smedira NG et al (2015) Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography. Am Heart J 169(5):684–692.e1 PubMed Masri A, Pierson LM, Smedira NG et al (2015) Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography. Am Heart J 169(5):684–692.e1 PubMed
138.
Zurück zum Zitat Coats CJ, Rantell K, Bartnik A et al (2015) Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy. Circ Heart Fail 8(6):1022–1031 PubMed Coats CJ, Rantell K, Bartnik A et al (2015) Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy. Circ Heart Fail 8(6):1022–1031 PubMed
139.
Zurück zum Zitat Magrì D, Limongelli G, Re F et al (2016) Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy. Heart 102(8):602–609 PubMed Magrì D, Limongelli G, Re F et al (2016) Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy. Heart 102(8):602–609 PubMed
140.
Zurück zum Zitat Brito D (2017) Predicting risk of sudden death in hypertrophic cardiomyopathy: can additional simple markers help? Rev Port Cardiol 36(4):247–249 PubMed Brito D (2017) Predicting risk of sudden death in hypertrophic cardiomyopathy: can additional simple markers help? Rev Port Cardiol 36(4):247–249 PubMed
141.
Zurück zum Zitat Cambronero F, Marín F, Roldán V et al (2009) Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur Heart J 30(2):139–151 PubMed Cambronero F, Marín F, Roldán V et al (2009) Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur Heart J 30(2):139–151 PubMed
142.
Zurück zum Zitat EXpert Group on Biomarkers (2014) Biomarkers in cardiology—part 1—in heart failure and specific cardiomyopathies. Arq Bras Cardiol 103(6):451–459 PubMedCentral EXpert Group on Biomarkers (2014) Biomarkers in cardiology—part 1—in heart failure and specific cardiomyopathies. Arq Bras Cardiol 103(6):451–459 PubMedCentral
143.
Zurück zum Zitat Brito D, Matias JS, Sargento L et al (2004) Plasma N‑terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy. Rev Port Cardiol 23(12):1557–1582 PubMed Brito D, Matias JS, Sargento L et al (2004) Plasma N‑terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy. Rev Port Cardiol 23(12):1557–1582 PubMed
144.
Zurück zum Zitat Ozyilmaz S, Akgul O, Uyarel H et al (2017) The importance of the neutrophil-to-lymphocyte ratio in patients with hypertrophic cardiomyopathy. Rev Port Cardiol 36(4):239–246 PubMed Ozyilmaz S, Akgul O, Uyarel H et al (2017) The importance of the neutrophil-to-lymphocyte ratio in patients with hypertrophic cardiomyopathy. Rev Port Cardiol 36(4):239–246 PubMed
145.
Zurück zum Zitat Colan SD, Lipshultz SE, Lowe AM et al (2007) Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 115(6):773–781 PubMed Colan SD, Lipshultz SE, Lowe AM et al (2007) Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 115(6):773–781 PubMed
146.
Zurück zum Zitat Maron BJ, Spirito P, Ackerman MJ, et al (2013) Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 61(14):1527–1535 PubMed Maron BJ, Spirito P, Ackerman MJ, et al (2013) Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 61(14):1527–1535 PubMed
147.
Zurück zum Zitat Decker JA, Rossano JW, Smith EO et al (2009) Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. J Am Coll Cardiol 54(3):250–254 PubMed Decker JA, Rossano JW, Smith EO et al (2009) Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. J Am Coll Cardiol 54(3):250–254 PubMed
148.
Zurück zum Zitat Ostman-Smith I, Wettrell G, Keeton B et al (2005) Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly. Cardiol Young 15(6):632–642 PubMed Ostman-Smith I, Wettrell G, Keeton B et al (2005) Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly. Cardiol Young 15(6):632–642 PubMed
149.
Zurück zum Zitat Dewland TA, Pellegrini CN, Wang Y et al (2011) Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. J Am Coll Cardiol 58(10):1007–1013 PubMed Dewland TA, Pellegrini CN, Wang Y et al (2011) Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. J Am Coll Cardiol 58(10):1007–1013 PubMed
150.
Zurück zum Zitat Norrish G, Cantarutti N, Pissaridou E et al (2017) Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: a systematic review and meta-analysis. Eur J Prev Cardiol 24(11):1220–1230 PubMed Norrish G, Cantarutti N, Pissaridou E et al (2017) Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: a systematic review and meta-analysis. Eur J Prev Cardiol 24(11):1220–1230 PubMed
151.
Zurück zum Zitat Schinkel AFL, Vriesendorp PA, Sijbrands EJG et al (2012) Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. Circ Heart Fail 5(5):552–559 PubMed Schinkel AFL, Vriesendorp PA, Sijbrands EJG et al (2012) Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. Circ Heart Fail 5(5):552–559 PubMed
152.
Zurück zum Zitat Konstantinou DM, Efthimiadis GK, Vassilikos V et al (2016) Implantable cardioverter defibrillators for primary prevention of sudden death in hypertrophic cardiomyopathy. J Cardiovasc Med 17(6):433–439 Konstantinou DM, Efthimiadis GK, Vassilikos V et al (2016) Implantable cardioverter defibrillators for primary prevention of sudden death in hypertrophic cardiomyopathy. J Cardiovasc Med 17(6):433–439
153.
Zurück zum Zitat Wilkoff BL, Fauchier L, Stiles MK et al (2016) 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm 13(2):e50–e86 PubMed Wilkoff BL, Fauchier L, Stiles MK et al (2016) 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm 13(2):e50–e86 PubMed
Metadaten
Titel
Risk stratification in hypertrophic cardiomyopathy
verfasst von
S. Marrakchi
I. Kammoun
E. Bennour
L. Laroussi
S. Kachboura
Publikationsdatum
25.04.2018
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe 1/2020
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-018-4700-8